Mark T. Reding
YOU?
Author Swipe
View article: HTRS2025.P2.59 Use of Therapeutic Plasma Exchange to Reduce or Prevent Bleeding Events in Rare Acquired FXIII-Related Bleeding Disorders
HTRS2025.P2.59 Use of Therapeutic Plasma Exchange to Reduce or Prevent Bleeding Events in Rare Acquired FXIII-Related Bleeding Disorders Open
View article: HTRS2025.P2.79 Fifth Interim Analysis of the HEM-POWR Study: Evaluating Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Patients With Severe and Nonsevere Hemophilia A in the United States
HTRS2025.P2.79 Fifth Interim Analysis of the HEM-POWR Study: Evaluating Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Patients With Severe and Nonsevere Hemophilia A in the United States Open
View article: Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing <scp>HEM</scp> ‐ <scp>POWR</scp> Study
Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing <span>HEM</span> ‐ <span>POWR</span> Study Open
Objectives To assess the effectiveness and safety of damoctocog alfa pegol in patients with severe and nonsevere hemophilia A in the fifth interim analysis of the ongoing HEM‐POWR study. Methods HEM‐POWR (NCT03932201) is a multinational, P…
View article: Characterization and management of patients with hereditary factor X deficiency: A case series
Characterization and management of patients with hereditary factor X deficiency: A case series Open
Background Hereditary factor X deficiency (HFXD) is an ultra‐rare, autosomal recessive bleeding disorder that results in reduced factor X coagulant activity (FX:C). HFXD is traditionally classified by severity as severe (FX:C <1%), moderat…
View article: Recombinant factor VIIa: new insights into the mechanism of action through product innovation
Recombinant factor VIIa: new insights into the mechanism of action through product innovation Open
View article: Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review Open
View article: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review Open
View article: Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–&lt;18 Years at Enrolment into PROTECT VIII
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII Open
Introduction: The phase 2/3 PROTECT VIII study demonstrated long-term efficacy and safety of damoctocog alfa pegol (BAY 94-9027; Jivi®), a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylat…
View article: Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A Open
View article: Interim analyses of the multinational real‐world prospective cohort <scp>HEM‐POWR</scp> study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A
Interim analyses of the multinational real‐world prospective cohort <span>HEM‐POWR</span> study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A Open
Objectives To assess effectiveness and safety of damoctocog alfa pegol in interim analyses of the ongoing real‐world hemophilia A HEM‐POWR study. Methods HEM‐POWR (NCT03932201) is a multinational Phase 4 prospective observational study. Th…
View article: OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1
OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1 Open
Conclusion(s):We succeeded in producing FVIII expressing platelets and partially corrected HemA phenotype in mice via IN delivery of G-F8-LVs in the lung.FVIII expression and storage in platelet α-granules can protect FVIII from naturalizi…
View article: PB0323 Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta
PB0323 Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta Open
Background: Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare thrombotic disorder caused by an inherited deficiency of the von Willebrand factor-cleaving enzyme ADAMTS13.Aims: To synthesize knowledge on the disease bur…
View article: PO19 Clinical Experiences in Managing the Transition to rIX-FP: Switching, Surgical Management and On-Demand
PO19 Clinical Experiences in Managing the Transition to rIX-FP: Switching, Surgical Management and On-Demand Open
View article: PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study
PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Study Open
View article: HTRS2023.O8C.2 Eptacog beta efficacy and safety in underweight, normal weight, and overweight/obese persons with hemophilia A or B and inhibitors
HTRS2023.O8C.2 Eptacog beta efficacy and safety in underweight, normal weight, and overweight/obese persons with hemophilia A or B and inhibitors Open
View article: HTRS2023.P2.22 Evaluating the effectiveness and safety of damoctocog alfa pegol prophylaxis in hemophilia A patients with a history of factor VIII inhibitors from the real-world HEM-POWR study
HTRS2023.P2.22 Evaluating the effectiveness and safety of damoctocog alfa pegol prophylaxis in hemophilia A patients with a history of factor VIII inhibitors from the real-world HEM-POWR study Open
View article: Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia Open
Collaborative research and care delivery will be key to capitalizing on current and horizon treatments and harnessing technical advances to improve diagnostics and testing, to advance health equity for all PWH.
View article: Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A Open
The study data show the durability of factor VIII activity and bleeding reduction and the safety profile of valoctocogene roxaparvovec at least 2 years after the gene transfer. Models of the risk of joint bleeding suggest that the relation…
View article: Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: <i>post hoc</i> analysis from the PROTECT VIII study
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: <i>post hoc</i> analysis from the PROTECT VIII study Open
Background: Advances in treatment have enabled patients with haemophilia A to live longer and therefore may be subjected to comorbidities associated with ageing, in addition to disease-associated morbidities. There have been few reports to…
View article: A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report
A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report Open
We report long‐term follow‐up of a patient who underwent a tailored laparoscopic procedure for symptomatic cholelithiasis, massive splenomegaly, and a planned pregnancy. There were no complications, and the patient remained symptom‐free at…
View article: Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia Open
Decades of research have transformed hemophilia from severely limiting children’s lives to a manageable disorder compatible with a full, active life, for many in high-income countries. The direction of future research will determine whethe…
View article: Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature
Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature Open
Introduction People with non‐severe haemophilia appear to be under‐treated in many countries, and this may lead to joint damage and worsen quality of life. Aim To review literature for clotting factor replacement prophylaxis in people with…
View article: PB2326: SAFE AND EFFECTIVE PROPHYLAXIS WITH PLASMA-DERIVED FACTOR X CONCENTRATE IN AN ELDERLY PATIENT WITH HEREDITARY FACTOR X DEFICIENCY
PB2326: SAFE AND EFFECTIVE PROPHYLAXIS WITH PLASMA-DERIVED FACTOR X CONCENTRATE IN AN ELDERLY PATIENT WITH HEREDITARY FACTOR X DEFICIENCY Open
Background: Coagulation factor X, human is a plasma-derived factor X concentrate indicated to treat and prevent bleeding in individuals with hereditary factor X deficiency (HFXD). The ages of patients in whom data was collected in the init…
View article: Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective Open
This review compares the methodology of published clinical studies investigating the extended-half-life (EHL) factor VIII (FVIII) products, rFVIIIFc (efmoroctocog alfa, Elocta®/Eloctate®), BAY 94-9027 (damoctocog alfa pegol, Jivi®), BAX 85…
View article: Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies Open
Rare cases of COVID‐19 vaccinated individuals develop anti‐platelet factor 4 (PF4) antibodies that cause thrombocytopenia and thrombotic complications, a syndrome referred to as vaccine‐induced immune thrombotic thrombocytopenia (VITT). Cu…
View article: Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study Open
Regular prophylaxis with exogenous factor VIII (FVIII) is recommended for individuals with severe haemophilia A (HA), but standardised data are scarce. Here, we report real-world data from a global cohort. Participants were men ≥18 years o…
View article: PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors Open
Introduction Surgical procedures in persons with haemophilia A or B with inhibitors (PwHABI) require the use of bypassing agents (BPA) and carry a high risk of complications. Historically, only two BPAs have been available; these are repor…
View article: Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders
Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders Open
Rare, chronic diseases such as hemophilia and other congenital coagulation disorders require coordinated delivery of services for optimal outcomes. Hemophilia Treatment Centers (HTCs) are specialized, multidisciplinary health-care centers …
View article: Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study
Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study Open
Background Studies evaluating strategies for the rapid development, implementation, and evaluation of clinical decision support (CDS) systems supporting guidelines for diseases with a poor knowledge base, such as COVID-19, are limited. Obj…
View article: Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A Open
Introduction Haemophilia A is a rare bleeding disorder caused by defects in coagulation factor VIII (FVIII). Damoctocog alfa pegol (BAY 94–9027, Jivi, Bayer, Germany) is a site-specifically PEGylated, extended-half-life, recombinant FVIII,…